共 176 条
[1]
Pfreundschuh M(2006)CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379-391
[2]
Trumper L(2006)Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 3121-3127
[3]
Osterborg A(2010)Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Blood 116 2040-5
[4]
Pettengell R(2017)Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Blood 130 1800-1808
[5]
Trneny M(1993)A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 987-94
[6]
Imrie K(2020)International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI Blood 135 2041-2048
[7]
Habermann TM(2020)(18)F-FDG PET Dissemination features in diffuse large B-cell lymphoma are predictive of outcome J Nucl Med 61 40-45
[8]
Weller EA(2020)SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model Blood Adv 4 1082-1092
[9]
Morrison VA(2018)(18)F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin’s lymphoma as predictors of treatment outcome and survival Ann Nucl Med 32 410-416
[10]
Gascoyne RD(2020)High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma Blood Adv 4 2286-2296